Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Aug 9, 2011Report to be Included in Response to Lorcaserin CRL
SAN DIEGO, CA, and WOODCLIFF LAKE, NJ, August 9, 2011 - Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today results from a Pathology Working Group's (PWG) re-adjudication...
-
Aug 2, 2011
SAN DIEGO and WOODCLIFF LAKE, N.J., Aug. 2, 2011 -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the completion of a clinical study that measured lorcaserin...
-
Jul 29, 2011
Woodcliff Lake, NJ, July 29, 2011 - Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Refusal to File letter in response to the company's New Drug...
-
Jul 19, 2011
Tokyo, Japan, July 19, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") today announced the launch of its novel anticancer agent Halaven in Japan for the...
-
Jul 13, 2011
Woodcliff Lake, NJ, July 13, 2011 - Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) seeking...